This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

AVROBIO Inkomsten in het verleden

Verleden criteriumcontroles 3/6

AVROBIO is de winst gegroeid met een gemiddeld jaarlijks percentage van 14.5%, terwijl de Biotechs industrie de winst growing met 19% per jaar.

Belangrijke informatie

14.5%

Groei van de winst

24.6%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	n/a
Rendement op eigen vermogen	34.1%
Nettomarge	n/a
Laatste winstupdate	31 Mar 2024

Recente prestatie-updates uit het verleden

Geen updates

Recent updates

Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK

Oct 18

Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status

Sep 20

Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

Mar 08

AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise

Dec 25

We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth

Nov 23

AVROBIO readies $75M equity offering

Nov 19

AVROBIO EPS misses by $0.19

Nov 05

Opbrengsten en kosten

Hoe AVROBIO geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:AVRO Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	G+A Uitgaven	R&D-uitgaven
31 Mar 24	30	22	27
31 Dec 23	12	23	44
30 Sep 23	-4	26	61
30 Jun 23	-5	27	63
31 Mar 23	-101	31	70
31 Dec 22	-106	33	72
30 Sep 22	-109	35	73
30 Jun 22	-119	38	80
31 Mar 22	-122	38	84
31 Dec 21	-119	36	83
30 Sep 21	-119	35	84
30 Jun 21	-123	34	89
31 Mar 21	-121	33	87
31 Dec 20	-120	33	87
30 Sep 20	-114	31	85
30 Jun 20	-95	28	69
31 Mar 20	-82	24	61
31 Dec 19	-73	21	55
30 Sep 19	-66	18	51
30 Jun 19	-61	16	47
31 Mar 19	-55	14	42
31 Dec 18	-49	11	35
30 Sep 18	-40	8	29
30 Jun 18	-35	6	25
31 Mar 18	-27	5	19
31 Dec 17	-19	3	15

Kwaliteitswinsten: AVRO heeft een grote eenmalige winst van $75.9M wat gevolgen heeft voor de financiële resultaten van de laatste 12 maanden tot 31st March, 2024.

Groeiende winstmarge: AVRO is in het verleden winstgevend geweest.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: AVRO is de afgelopen 5 jaar winstgevend geworden en heeft de winst met 14.5% per jaar laten groeien.

Versnelling van de groei: AVRO is het afgelopen jaar winstgevend geworden, waardoor de winstgroei moeilijk te vergelijken is met het 5-jarig gemiddelde.

Winst versus industrie: AVRO is het afgelopen jaar winstgevend geworden, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs -sector ( -15% ).

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 34.1% ) van AVRO wordt als hoog beschouwd.

This company is no longer active

AVROBIO Inkomsten in het verleden

Verleden criteriumcontroles 3/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Recent updates

Tectonic Therapeutic, Inc. completed the acquisition of AVROBIO, Inc. (NasdaqGS:AVRO) from a group of shareholders in a reverse merger transaction.

Investor sentiment improves as stock rises 1,043%

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

No longer forecast to breakeven

Price target decreased by 16% to US$3.00

New major risk - Revenue and earnings growth

Chief Business Officer notifies of intention to sell stock

Novartis Pharma AG and Novartis Pharmaceuticals Corporation entered into an Asset Purchase Agreement to acquire Cystinosis Gene Therapy Program from AVROBIO, Inc. (NasdaqGS:AVRO) for $87.5 million.

Price target decreased by 8.5% to US$3.58

Novartis Pharma AG and Novartis Pharmaceuticals Corporation entered into an Asset Purchase Agreement to acquire Cystinosis Gene Therapy Program from AVROBIO, Inc. (NasdaqGS:AVRO) for $87.5 million.

Co- Founder exercised options to buy US$104k worth of stock.

AVROBIO, Inc. Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for Its Gaucher Disease Gene Therapy

Price target decreased to US$4.14

Insufficient new directors

Avrobio Receives Rare Pediatric Disease Designation from the U.S. FDA for First-In-Class Gene Therapy for Gaucher Disease

AVROBIO, Inc. Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis

AVROBIO, Inc. announces U.K. Medicines and Healthcare products Regulatory Agency grant an Innovation Passport under the Innovative Licensing and Access Pathway

Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK

AVROBIO, Inc. Reports Favorable Data on Use of Combined State-Of-The-Art in Vitro Cell-Based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development

AVROBIO Receives Written Notice from The Nasdaq Stock Market Regarding Minimum Bid Price Requirement

AVROBIO, Inc. Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for First Gene Therapy in Development for Cystinosis

Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status

AVROBIO Inc. Announces Neuronopathic Mucopolysaccharidosis Type II or Hunter Syndrome Clinical Trial Application Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial

AVROBIO granted FDA’s orphan drug designation for metabolic disorder therapy

AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell 2500 Index

AVROBIO, Inc. Announces Preclinical Data Demonstrating the Efficacy and Safety of AVR-RD-03 Gene Therapy in A Mouse Model of Infantile Onset Pompe Disease

Avrobio Reports Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures

Price target decreased to US$6.29

Insufficient new directors

AVROBIO, Inc. Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis

Insufficient new directors

Insufficient new directors

AVROBIO, Inc. Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer

AVROBIO, Inc. Announces New Data from Phase 2 Fab-Gt Clinical Trial Show Variable Engraftment

AVROBIO, Inc Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1

Price target decreased to US$22.88

Price target increased to US$25.14

Here's Why We're Watching AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

We're Keeping An Eye On AVROBIO's (NASDAQ:AVRO) Cash Burn Rate

AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell 2500 Growth Index

AVROBIO: Fabrazyme's Full Approval Changes Things

AVROBIO, Inc. Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease

AVROBIO, Inc. Announces Two Oral Presentations and Two Posters Featuring Data from Its Pipeline of Lysosomal Disorder Gene Therapy

Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

Price target lowered to US$34.50

AVROBIO, Inc. Receives Orphan Drug Designation from the European Commission for AVR-RD-04, an Investigational Gene Therapy for Cystinosis

AVROBIO, Inc. Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato Gene Therapy Platform in Fabry Disease Phase 2 Trial

New 90-day high: US$17.11

Avrobio Appoints Diana M. Escolar as Chief Medical Officer

AVROBIO, Inc. Appoints Diana M. Escolar as Chief Medical Officer

AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise

We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth

AVROBIO readies $75M equity offering

AVROBIO, Inc. Avrobio Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline

AVROBIO EPS misses by $0.19

Price target raised to US$38.50

Avrobio, Inc. Enters into Agreement with University of Manchester, England

Avrobio, Inc. Receives Orphan Drug Designation from the European Medicines Agency for Avr-Rd-02, an Investigational Gene Therapy for Gaucher Disease

New 90-day low: US$15.00

New 90-day low - US$15.85

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden